ONCO.ST
Oncopeptides AB (publ) [ONCO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ONCO.ST Stock Summary
Top 10 Correlated Stocks
ONCO.ST
In the News
ONCO.ST Financial details
Company Rating
Neutral
Market Cap
427.94M
Income
-259M
Revenue
30.44M
Book val./share
1.47
Cash/share
2.58
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-2.58
Forward P/E
-
PEG
0.3
P/S
22.38
P/B
5.01
P/C
1.55
P/FCF
-2.26
Quick Ratio
5.59
Current Ratio
6.68
Debt / Equity
0.81
LT Debt / Equity
0.81
-
-
EPS (TTM)
-2.87
EPS next Y
-
EPS next Q
-
EPS this Y
-78.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-89.19%
EPS Q/Q
-27.42%
-
-
-
-
SMA20
33.33%
SMA50
-20%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-88%
ROE
-124%
ROC
-1.08%
Gross Margin
106%
Oper. Margin
-897%
Profit Margin
-851%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-11.87
52W High
-63.64%
52W Low
0%
RSI
52
Rel Volume
3.52
Avg Volume
435.2K
Volume
1.53M
Perf Week
14.94%
Perf Month
-11.89%
Perf Quarter
-19.52%
Perf Half Y
-25.09%
-
-
-
-
Beta
-0.605
-
-
Volatility
0.46%, 0.52%
Prev Close
-11.89%
Price
4
Change
-11.89%
ONCO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 1.57 | 0.1 | |
| Net income per share | -9.77 | -14.33 | -25.57 | -19 | -4.11 | |
| Operating cash flow per share | -7.77 | -13.36 | -20.79 | -20.14 | -5.11 | |
| Free cash flow per share | -7.78 | -13.41 | -21.06 | -20.14 | -5.14 | |
| Cash per share | 8.75 | 17.91 | 13.67 | 4.84 | 4.19 | |
| Book value per share | 7.36 | 15.42 | 9.25 | 2.8 | 3.57 | |
| Tangible book value per share | 7.36 | 15.37 | 9.22 | 2.78 | 3.57 | |
| Share holders equity per share | 7.36 | 15.42 | 9.25 | 2.8 | 3.57 | |
| Interest debt per share | 0 | 0.14 | 0.33 | 0.2 | 0.13 | |
| Market cap | 5.67B | 6.56B | 10.58B | 632.45M | 1B | |
| Enterprise value | 5.29B | 5.64B | 9.76B | 284.46M | 665.22M | |
| P/E ratio | -13.51 | -8.86 | -6.64 | -0.44 | -2.96 | |
| Price to sales ratio | 0 | 0 | 0 | 5.35 | 119.71 | |
| POCF ratio | -16.98 | -9.5 | -8.16 | -0.42 | -2.38 | |
| PFCF ratio | -16.96 | -9.46 | -8.06 | -0.42 | -2.36 | |
| P/B Ratio | 17.94 | 8.23 | 18.35 | 3 | 3.4 | |
| PTB ratio | 17.94 | 8.23 | 18.35 | 3 | 3.4 | |
| EV to sales | 0 | 0 | 0 | 2.4 | 79.62 | |
| Enterprise value over EBITDA | -12.63 | -7.68 | -6.19 | -0.2 | -2.08 | |
| EV to operating cash flow | -15.85 | -8.17 | -7.53 | -0.19 | -1.58 | |
| EV to free cash flow | -15.84 | -8.14 | -7.43 | -0.19 | -1.57 | |
| Earnings yield | -0.07 | -0.11 | -0.15 | -2.26 | -0.34 | |
| Free cash flow yield | -0.06 | -0.11 | -0.12 | -2.4 | -0.42 | |
| Debt to equity | 0 | 0.01 | 0.03 | 0.07 | 0.03 | |
| Debt to assets | 0 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Net debt to EBITDA | 0.9 | 1.25 | 0.52 | 0.25 | 1.05 | |
| Current ratio | 3.88 | 5.88 | 2.52 | 1.83 | 4.25 | |
| Interest coverage | -209.65K | -1.4K | -1.07K | -1.5K | -395.64 | |
| Income quality | 0.8 | 0.93 | 0.81 | 1.07 | 1.2 | |
| Dividend Yield | 0 | 0.01 | 0.01 | 0.13 | 0.04 | |
| Payout ratio | 0 | -0.1 | -0.05 | -0.06 | -0.13 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 1.48 | 10.06 | |
| Research and developement to revenue | 0 | 0 | 0 | 5.75 | 26.05 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.3 | |
| Capex to depreciation | -1.07 | -0.58 | -1.19 | -0.02 | -0.15 | |
| Stock based compensation to revenue | 0 | 0 | 0 | -0.29 | 2.29 | |
| Graham number | 40.22 | 70.49 | 72.95 | 34.6 | 18.17 | |
| ROIC | -1.33 | -0.91 | -2.59 | -5.98 | -1.12 | |
| Return on tangible assets | -0.94 | -0.75 | -1.69 | -3.27 | -0.88 | |
| Graham Net | 5.75 | 14.22 | 8.09 | 2.18 | 3.24 | |
| Working capital | 327.48M | 805.71M | 540.4M | 187.08M | 278.36M | |
| Tangible asset value | 315.83M | 794.9M | 575.07M | 209.46M | 294.29M | |
| Net current asset value | 312.62M | 774.41M | 524.94M | 183.87M | 273M | |
| Invested capital | 0 | 0.01 | 0.03 | 0.07 | 0.03 | |
| Average receivables | 0 | 3.49M | 15.1M | 30.61M | 27.63M | |
| Average payables | 20.48M | 53.13M | 108.56M | 85.92M | 31.96M | |
| Average inventory | 0 | 0 | 4.33M | 4.33M | 0.5 | |
| Days sales outstanding | 0 | 0 | 0 | 117.24 | 754.38 | |
| Days payables outstanding | 0 | 6.51K | 3.45K | 245.31 | 1.72M | |
| Days of inventory on hand | 0 | 0 | 219.59 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 3.11 | 0.48 | |
| Payables turnover | 0 | 0.06 | 0.11 | 1.49 | 0 | |
| Inventory turnover | 0 | 0 | 1.66 | 53.12M | 0 | |
| ROE | -1.33 | -0.93 | -2.76 | -6.78 | -1.15 | |
| Capex per share | -0.01 | -0.05 | -0.28 | 0 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.01 | 0.29 | 0.03 | |
| Net income per share | -1 | -1.01 | -0.79 | -0.62 | -0.45 | |
| Operating cash flow per share | -0.8 | -0.86 | -0.98 | -0.86 | -0.64 | |
| Free cash flow per share | -0.8 | -0.89 | -0.98 | -0.86 | -0.64 | |
| Cash per share | 4.83 | 3.82 | 2.79 | 3.25 | 2.58 | |
| Book value per share | 4.3 | 3.26 | 2.53 | 1.96 | 1.47 | |
| Tangible book value per share | 4.3 | 3.26 | 2.53 | 1.96 | 1.47 | |
| Share holders equity per share | 4.3 | 3.26 | 2.53 | 1.96 | 1.47 | |
| Interest debt per share | 0.01 | 0 | -0.01 | 1.21 | 1.23 | |
| Market cap | 1.05B | 1.1B | 997.67M | 784.4M | 780.49M | |
| Enterprise value | 617.96M | 763.01M | 821.3M | 730.47M | 727.33M | |
| P/E ratio | -2.96 | -3.01 | -3.51 | -3.48 | -4.81 | |
| Price to sales ratio | 0 | 1.96K | 887.61 | 30.22 | 278.25 | |
| POCF ratio | -14.76 | -14.14 | -11.21 | -10.15 | -13.5 | |
| PFCF ratio | -14.76 | -13.7 | -11.21 | -10.15 | -13.5 | |
| P/B Ratio | 2.75 | 3.73 | 4.37 | 4.43 | 5.85 | |
| PTB ratio | 2.75 | 3.73 | 4.37 | 4.43 | 5.85 | |
| EV to sales | 0 | 1.36K | 730.69 | 28.14 | 259.3 | |
| Enterprise value over EBITDA | -6.95 | -8.67 | -11.29 | -11.7 | -19.5 | |
| EV to operating cash flow | -8.73 | -9.83 | -9.23 | -9.45 | -12.59 | |
| EV to free cash flow | -8.73 | -9.52 | -9.23 | -9.45 | -12.59 | |
| Earnings yield | -0.08 | -0.08 | -0.07 | -0.07 | -0.05 | |
| Free cash flow yield | -0.07 | -0.07 | -0.09 | -0.1 | -0.07 | |
| Debt to equity | 0 | 0.03 | 0 | 0.62 | 0.81 | |
| Debt to assets | 0 | 0.02 | 0 | 0.31 | 0.37 | |
| Net debt to EBITDA | 4.81 | 3.81 | 2.42 | 0.86 | 1.43 | |
| Current ratio | 5.06 | 4.25 | 3.53 | 5.86 | 6.68 | |
| Interest coverage | -169.89 | 10.76 | 155.43 | 0 | -11.9 | |
| Income quality | 0.8 | 0.77 | 1.22 | 1.24 | 1.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 36.41 | 19.4 | 0.73 | 4.34 | |
| Research and developement to revenue | 0 | 102.08 | 26.75 | 1.45 | 2.24 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.03 | 0 | 0 | 0 | |
| Capex to revenue | 0 | -4.48 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -0.15 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 12.4 | 4.36 | 0.2 | 0 | |
| Graham number | 9.84 | 8.59 | 6.69 | 5.24 | 3.86 | |
| ROIC | -0.23 | -0.32 | -0.31 | -0.22 | -0.15 | |
| Return on tangible assets | -0.19 | -0.24 | -0.22 | -0.16 | -0.14 | |
| Graham Net | 3.83 | 2.95 | 2.16 | 1.63 | 1.17 | |
| Working capital | 365.06M | 278.36M | 212.81M | 280.2M | 237.08M | |
| Tangible asset value | 380.26M | 294.29M | 228.42M | 177.13M | 133.4M | |
| Net current asset value | 359.17M | 273M | 208.4M | 159.02M | 117.26M | |
| Invested capital | 0 | 0.03 | 0 | 0.62 | 0.81 | |
| Average receivables | 29.63M | 22.39M | 29.6M | 42.02M | 42.72M | |
| Average payables | 15.68M | 24.76M | 23.88M | 19.71M | 16.22M | |
| Average inventory | -29.63M | -13.76M | 516.5K | 1.52M | 1.96M | |
| Days sales outstanding | 0 | 2.78K | 3.36K | 146.08 | 1.39K | |
| Days payables outstanding | 0 | 423.29K | 159.84K | 71.59K | -596.16 | |
| Days of inventory on hand | 0 | 0 | 8.45K | 7.2K | -91.33 | |
| Receivables turnover | 0 | 0.03 | 0.03 | 0.62 | 0.06 | |
| Payables turnover | 0 | 0 | 0 | 0 | -0.15 | |
| Inventory turnover | 0 | 0 | 0.01 | 0.01 | -0.99 | |
| ROE | -0.23 | -0.31 | -0.31 | -0.32 | -0.3 | |
| Capex per share | 0 | -0.03 | 0 | 0 | 0 |
ONCO.ST Frequently Asked Questions
What is Oncopeptides AB (publ) stock symbol ?
Oncopeptides AB (publ) is a SE stock and trading under the symbol ONCO.ST
What is Oncopeptides AB (publ) stock quote today ?
Oncopeptides AB (publ) stock price is $4 today.
Is Oncopeptides AB (publ) stock public?
Yes, Oncopeptides AB (publ) is a publicly traded company.
Company Profile
- Volume Average 435.2K
- Market Capitalization 427.94M
- Employee 57
- CEO Ms. Sofia Heigis M.Sc.
- Headquarters Stockholm,SE
- IPO Date 2017-02-22
-
Website
https://www.oncopeptides.com/sv 
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
